Shenmiao Yang

750 total citations
37 papers, 296 citations indexed

About

Shenmiao Yang is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Shenmiao Yang has authored 37 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 15 papers in Hematology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Shenmiao Yang's work include Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (12 papers) and Acute Myeloid Leukemia Research (7 papers). Shenmiao Yang is often cited by papers focused on Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (12 papers) and Acute Myeloid Leukemia Research (7 papers). Shenmiao Yang collaborates with scholars based in China, United Kingdom and United States. Shenmiao Yang's co-authors include Xiao‐Jun Huang, Robert Peter Gale, Jianyong Li, Wei Xu, Haiwen Huang, Keshu Zhou, Ru Feng, Jianfeng Zhou, Ling Pan and Jianda Hu and has published in prestigious journals such as Advanced Materials, Blood and Medical Physics.

In The Last Decade

Shenmiao Yang

33 papers receiving 290 citations

Peers

Shenmiao Yang
Aileen Cohen United States
Márcia Torresan Delamain Brazil
M. Maynadié France
Masa Lasica Australia
G. Doreen te Raa Netherlands
Florence Broussais‐Guillaumot France
Emma Verner Australia
Guy Cantin Canada
Parveen Bose India
Zdravko Mitrović Croatia
Aileen Cohen United States
Shenmiao Yang
Citations per year, relative to Shenmiao Yang Shenmiao Yang (= 1×) peers Aileen Cohen

Countries citing papers authored by Shenmiao Yang

Since Specialization
Citations

This map shows the geographic impact of Shenmiao Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shenmiao Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shenmiao Yang more than expected).

Fields of papers citing papers by Shenmiao Yang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shenmiao Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shenmiao Yang. The network helps show where Shenmiao Yang may publish in the future.

Co-authorship network of co-authors of Shenmiao Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Shenmiao Yang. A scholar is included among the top collaborators of Shenmiao Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shenmiao Yang. Shenmiao Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huang, H. K., Shenmiao Yang, Jiaofen Nan, et al.. (2025). 3D lymphoma segmentation on PET/CT images via multi‐scale information fusion with cross‐attention. Medical Physics. 52(6). 4371–4389.
2.
Zhou, Jian, Feng‐Rong Wang, Shenmiao Yang, et al.. (2025). Survival outcomes between haploidentical stem cell transplantation and chemotherapy for blastic plasmacytoid dendritic cell neoplasm. Bone Marrow Transplantation. 60(5). 568–572.
3.
Li, Weichang, Shenmiao Yang, Taolin Sun, et al.. (2025). A Microphase Separation‐Driven Supramolecular Tissue Adhesive with Instantaneous Dry/Wet Adhesion, Alcohol‐Triggered Debonding, and Antibacterial Hemostasis. Advanced Materials. 37(28). e2501810–e2501810. 4 indexed citations
4.
Yang, Shenmiao, Haiwen Huang, Keshu Zhou, et al.. (2024). Acalabrutinib in Chinese patients with relapsed/refractory chronic lymphocytic leukemia: Primary analysis from an open-label, multicenter phase 1/2 trial. Annals of Hematology. 104(1). 701–712. 1 indexed citations
5.
Yang, Shenmiao, et al.. (2024). The impact of Bruton’s tyrosine kinase inhibitor treatment on COVID-19 outcomes in Chinese patients with chronic lymphocytic leukemia. Frontiers in Oncology. 14. 1396913–1396913. 1 indexed citations
6.
7.
Yang, Shenmiao, Neil E. Kay, Min Shi, Curtis A. Hanson, & Robert Peter Gale. (2022). Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (CLL)?. Leukemia. 36(11). 2743–2747. 2 indexed citations
8.
Yang, Shenmiao, Xiao‐Jun Huang, & Robert Peter Gale. (2021). Cell therapy of chronic lymphocytic leukaemia: Transplants and chimeric antigen receptor (CAR)-T cells. Blood Reviews. 51. 100884–100884. 1 indexed citations
9.
Yang, Shenmiao, Rong Zhu, Nan Li, et al.. (2021). Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation. Acta Haematologica. 145(1). 54–62. 5 indexed citations
10.
Yang, Shenmiao, et al.. (2020). Ethnic and geographic diversity of chronic lymphocytic leukaemia. Leukemia. 35(2). 433–439. 27 indexed citations
11.
Dong, Dong, Jun Jin, Simone Oerlemans, et al.. (2020). Validation of the Chinese EORTC chronic lymphocytic leukaemia module – application of classical test theory and item response theory. Health and Quality of Life Outcomes. 18(1). 96–96. 3 indexed citations
12.
Yang, Shenmiao, et al.. (2020). The prognostic significance of ΔSUVmax assessed by PET/CT scan after 2 cycles of chemotherapy in patients with classic Hodgkin’s lymphoma. Annals of Hematology. 99(2). 293–299. 6 indexed citations
13.
Xu, Wei, Shenmiao Yang, Keshu Zhou, et al.. (2020). Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. Journal of Hematology & Oncology. 13(1). 48–48. 92 indexed citations
14.
Yang, Shenmiao, Dong Dong, Hongfei Gu, et al.. (2020). Impact of stopping therapy during the SARS-CoV-2 pandemic in persons with lymphoma. Journal of Cancer Research and Clinical Oncology. 147(5). 1469–1479. 9 indexed citations
15.
Yang, Shenmiao, Robert Peter Gale, Hongxia Shi, et al.. (2018). Is there an epidemic of chronic lymphocytic leukaemia (CLL) in China?. Leukemia Research. 73. 16–20. 11 indexed citations
16.
Shen, Danhua, et al.. (2018). Clinicopathological features of splenic tumours of lymphoid tissue. Pathology - Research and Practice. 214(12). 1952–1958. 5 indexed citations
17.
Liu, Jiangying, Ya‐Zhen Qin, Shenmiao Yang, et al.. (2017). Meis1 is critical to the maintenance of human acute myeloid leukemia cells independent of MLL rearrangements. Annals of Hematology. 96(4). 567–574. 16 indexed citations
18.
Jiang, Bin, Kai‐Yan Liu, Lan‐Ping Xu, et al.. (2015). [Outcome of patients with adult acute lymphoblastic leukemia between 2000 and 2013: experience from single center].. PubMed. 36(9). 726–32. 4 indexed citations
19.
Yang, Shenmiao, Jianyong Li, Robert Peter Gale, & Xiao‐Jun Huang. (2014). The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?. Blood Reviews. 29(3). 205–213. 46 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aileen Cohen Breakdown of academic impact, for papers by Márcia Torresan Delamain Breakdown of academic impact, for papers by M. Maynadié Breakdown of academic impact, for papers by Masa Lasica Breakdown of academic impact, for papers by G. Doreen te Raa Breakdown of academic impact, for papers by Florence Broussais‐Guillaumot Breakdown of academic impact, for papers by Emma Verner Breakdown of academic impact, for papers by Guy Cantin Breakdown of academic impact, for papers by Parveen Bose Breakdown of academic impact, for papers by Zdravko Mitrović
Rankless by CCL
2026